Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in hematology"
DOI: 10.1053/j.seminhematol.2017.06.003
Abstract: Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting… read more here.
Keywords: non del; del; del mds; myelodysplastic syndromes ... See more keywords